English

Abstract

Tumour necrosis factor alpha (TNFα) antagonists are biological response modifiers increasingly used to effectively treat a wide array of inflammatory diseases such as Crohn’s disease and rheumatoid arthritis. Anti-TNFα agents are also used in the treatment of steroidrefractory granulomatous diseases, with reported success. Paradoxically, an increasing number of cases of anti-TNF–induced sarcoidosis are being reported. The acute form of sarcoidosis, Lofgren syndrome, is characterized by mediastinal adenopathy, erythema nodosum, arthralgia, and fever. This article describes the case of a patient with Crohn's disease who developed Lofgren syndrome during treatment with infliximab. To our knowledge, this is the first case of Lofgren syndrome developing during treatment with a TNFα antagonist.